XML 36 R19.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Balance Sheet Details | 12 Months Ended
--- | ---
Dec. 31, 2024
Balance Sheet Related Disclosures [Abstract] |
Balance Sheet Details | Balance Sheet Details Inventories Inventories consisted of the following (in thousands):
| December 31,
| 2024 |  | 2023
Raw materials | $ | — |  |  | $ | 108 |
Work in process | 29 |  |  | 7 |
Finished goods | 1,770 |  |  | 2,570 |
Total inventories | $ | 1,799 |  |  | $ | 2,685 |
Prepaid expenses and other current assets As of December 31, 2024, prepaid expenses and other current assets consists of prepaid expenses of $3.7 million and other current assets of $0.5 million. As of December 31, 2023, prepaid expenses and other current assets consists of prepaid expenses of $4.6 million and other current assets of $0.6 million. Property and Equipment, net Property and equipment, net consisted of the following (in thousands):
| December 31,
| 2024 |  | 2023
Laboratory equipment(1) | $ | 35,949 |  |  | $ | 37,216 |
Leasehold improvements | 12,159 |  |  | 11,912 |
Computer equipment | 2,459 |  |  | 2,565 |
Office furniture and equipment | 1,124 |  |  | 1,469 |
Construction in progress(2) | 3,441 |  |  | 1,636 |
Property and Equipment | 55,132 |  |  | 54,798 |
Less: accumulated depreciation | (40,935) |  |  | (39,311) |
Property and equipment, net | $ | 14,197 |  |  | $ | 15,487 |
(1) Fully depreciated property and equipment with a cost of $2.6 million and $3.0 million were retired during the years ended December 31, 2024 and 2023, respectively. (2) Construction in progress includes equipment received but not yet placed into service pending installation. In July 2023, we announced our plan to consolidate operations from our San Carlos facility to our headquarters in Redwood City. As part of this plan, we entered into agreements to sell certain laboratory equipment located in our San Carlos facility through an asset auction and as part of the lease assignment of the San Carlos facility to Vaxcyte (see further discussion at Note 13, “Commitments and Contingencies”). These certain items of laboratory equipment met the assets held for sale criteria and were sold during the fourth quarter of 2023. Using a fair value estimate based on Level 3 inputs in the fair value hierarchy, the Company determined that the carrying value of these assets exceeded fair value less costs to sell, which resulted in a write-down o f $1.5 million, presented within the asset impairment and other charges line item in the consolidated statements of operations in the year ended December 31, 2023. During the year ended December 31, 2023, the Company recorded a n on-cash impairment charge of $4.7 million associated with the San Carlos facility leasehold improvements. For additional information, see Note 13, “Commitments and Contingencies.” Depreciation expense included in both research and development expenses and selling, general and administrative expenses in the consolidated statements of operations was as follows (in thousands):
| Year Ended December 31,
| 2024 |  | 2023 |  | 2022
Research and development | $ | 3,964 |  |  | $ | 4,594 |  |  | $ | 4,556 |
Selling, general and administrative | 881 |  |  | 924 |  |  | 846 |
Total depreciation expense | $ | 4,845 |  |  | $ | 5,518 |  |  | $ | 5,402 |
Goodwill
| December 31,
| 2024 |  | 2023
Goodwill at beginning of period | $ | 2,463 |  |  | $ | 3,241 |
Impairment | — |  |  | (778) |
Goodwill at end of period | $ | 2,463 |  |  | $ | 2,463 |
Goodwill was previously allocated to each of the Company's reporting units. In July 2023, we announced a restructuring of our business and that we are discontinuing investment in certain development programs, primarily in Novel Biotherapeutics. As a result of this plan, the Company determined that a triggering event had occurred that required an interim goodwill impairment test during the third quarter of 2023. The fair value estimate used in the interim goodwill impairment test was primarily based on Level 3 inputs in the fair value hierarchy. Based on the results of the impairment evaluation, the Company determined that the goodwill within the Novel Biotherapeutics reporting unit was impaired, which resulted in a non-cash impairment charge of $0.8 million to write off all of the associated goodwill. The impairment charge is recorded within the asset impairment and other charges in the consolidated statements of operation in the year ended December 31, 2023. Goodwill had a carrying value of $2.5 million as of December 31, 2024 and 2023, respectively. Other Accrued Liabilities Other accrued liabilities consisted of the following (in thousands):
| December 31,
| 2024 |  | 2023
Accrued professional and outside service fees | $ | 3,064 |  |  | $ | 2,330 |
Accrued purchases | 2,908 |  |  | 1,402 |
Other | 251 |  |  | 1,003 |
Total other accrued liabilities | $ | 6,223 |  |  | $ | 4,735 |

X
- References No definition available. + Details
Name: | us-gaap_BalanceSheetRelatedDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/210/tableOfContent + Details
Name: | us-gaap_SupplementalBalanceSheetDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration